Pharmaceutical Industry Reports Monoclonal Antibody Therapeutics Market | Page 2

REPORT DESCRIPTION
Monoclonal Antibody Therapeutics Market – Overview
Monoclonal antibodies are a type of immunotherapy, which are made in a laboratory and are several copies
of a single antibody. Several monoclonal antibodies to treat inflammatory, cancer, and other diseases have
been approved by the U.S. Food & Drug Administration (FDA). Depending on the source, there are four
types of monoclonal antibodies: Murine, Chimeric, Humanized, and Human. Murine antibodies are
entirely derived from a murine source, chimeric antibodies contain variable regions from murine origin and
constant regions from human origin. Humanized antibodies are derived from a human source with a small
part of a mouse or rat monoclonal antibody and human antibodies are entirely derived from a human
source.
Monoclonal antibodies are majorly used in cancer treatment along with certain inflammatory, infectious,
and other diseases. Depending upon the functions of monoclonal antibodies (for cancer) they are further
classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific
monoclonal antibodies. Commercially available monoclonal antibodies include, Iplimumab, Nivolumab,
Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
© Coherent market Insights. All Rights Reserved